Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT

Area of Science:

• Nuclear Medicine
• Oncology
• Radiochemistry

Background:

• Prostate-specific membrane antigen (PSMA)-targeted PET imaging has gained prominence in prostate cancer (PC) management.
• Regulatory approvals exist for PSMA PET in staging, recurrence detection, and treatment eligibility.
• Conventional imaging (CT, bone scan) and non-PSMA PET tracers have limitations in PC detection and response assessment.

Purpose of the Study:

• To evaluate the current applications and limitations of PSMA PET in prostate cancer.
• To discuss the appropriateness of existing response assessment criteria for PSMA PET in PC.
• To explore future directions for PSMA PET in PC therapy monitoring.

Main Methods:

• Review of current literature and regulatory approvals for PSMA PET in prostate cancer.
• Analysis of the utility of PSMA PET progression criteria and RECIP 1.0 in different treatment contexts.
• Discussion of the challenges in assessing treatment response with PSMA PET, especially with androgen signaling axis inhibitors.

Main Results:

• PSMA PET is approved for initial staging, recurrence detection, and guiding PSMA-targeted radiopharmaceutical therapy.
• Current response assessment methods are often inadequate for PC, and PSMA PET lacks specific regulatory approval for this use.
• PSMA PET progression criteria and RECIP 1.0 show value in cytotoxic therapy but have less clear roles with androgen-targeting agents due to variable PSMA expression.

Conclusions:

• PSMA PET is a crucial tool for staging and treatment selection in prostate cancer.
• Further research is needed to establish standardized response assessment criteria using PSMA PET.
• Machine learning and AI may identify novel imaging biomarkers from PSMA PET uptake changes during therapy.